NANOBIOTIX : Cancer poumon

jfox1

01:41

Conclusions

• NBTXR3 injection in both peripheral and central lung lesions was feasible and well tolerated
• One patient (1/29) experienced a procedure related pneumothorax requiring a chest tube

• NBTXR3/RT was also well tolerated in combination with anti-PD-1

• Among patients evaluable for efficacy, ORR was 51.9% in injected lesions, and 33.3% overall

• An ORR of 47.4% in injected lesions, and 26.3% overall was achieved in patients who were resistant to ICI

• Promising local control was observed, with DCR of 100% in injected lesions, and 74.1% overall

• Progressive disease was largely due to new lesions or non target lesions, with no progression observed in injected lesions

• These results support that NBTXR3 can be safely injected in the lung, with promising preliminary efficacy, particularly in local control

• These results warrant further evaluation of NBTXR3/RT in combination with ICI in a randomized trial
References
Biology, Physics. 2021. (4) Darmon A, et al., Cancer Cell Int. 2022. (5) Bonvalot S, et al., Lancet Oncol 2019.


Disclaimer
The scientific information discussed in this presentation related to NBTXR3 is preliminary and investigative. NBTXR3 is not approved by the US Food
and Drug Administration; therefore, no conclusions can nor should be drawn regarding the safety or effectiveness of the investigational product.


Acknowledgements
All participating centers, all site staff, all patients and their families
Contact Information
Nanobiotix Medical Affairs: medicalaffairs@nanobiotix.com
“Copies of this poster